GLP-1 Medications and Kidney Function Monitoring: What the Data Shows
Clinical follow-up on GLP-1 receptor agonist therapy increasingly includes a specific timeline: kidney function panels every three to six months during the first year of treatment, then annually once results stabilize. That cadence, now standard in prescribing guidance from providers managing large GLP-1 patient populations, reflects a shift in how weight-loss and diabetes medications are
GLP-1 Medications and Kidney Function Monitoring: What the Data Shows Read More »










